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Introduction
Although the liver is an organ of remarkable regenerative capaci-
ty, cell death–related compensatory tissue injury responses com-
monly culminate in fibrosis and eventually cirrhosis, a major 
cause of morbidity worldwide. With regard to this vital contribu-
tion of hepatocellular death to virtually all hepatic diseases, pre-
cise mechanistic knowledge of cell death regulation is essential 
to understand the pathophysiology of liver diseases. While for a 
long time apoptosis and necrosis were the most widely recog-
nized forms of cell death, the concept of regulated cell death was 
recently challenged by the discovery of necroptosis (1, 2). Necro-
ptosis has been described as a form of cell death mediated by 
the receptor-interacting protein kinase RIPK3 and mixed lineage 
kinase domain–like protein (MLKL) that is sensitized under cer-
tain conditions, such as caspase-8 inhibition (3–8). In the absence 
of functional caspase-8, receptor-interacting protein kinases 
(RIP kinases) drive the assembly of a macromolecular complex, 
the so-called necrosome (9). It is currently believed that necro-
some formation is a critical step during necroptosis, as it leads 
to recruitment and activation of the RIPK3 substrate MLKL (7). 
Activated MLKL subsequently forms oligomers and translocates 
to the plasma membrane and other membranous cellular struc-
tures to cause membrane disintegration, a critical step required for 
cell death execution (10, 11). While apoptosis is considered to be 
rather immunosuppressive, necroptosis has been suggested to be 
proinflammatory and to initiate inflammation. Accordingly, stud-
ies implicated necroptosis in the pathogenesis of several inflam-
matory diseases, such as inflammatory bowel disease and kidney 
diseases (8, 12–14). Conversely, the role of programmed necrotic 
cell death in human inflammatory liver diseases still remains to 
be fully elucidated (15). In patients suffering from drug-induced 
liver injury (DILI), cell death was demonstrated to be associated 
with activation of MLKL (16). However, the role of programmed 
hepatocellular death in acetaminophen-induced (APAP-induced) 
murine liver damage remains controversial. Although inhibition of 
necroptosis by deficiency of RIPK3 (17) or pharmacological block-
age of RIPK1 kinase activity (18) reduced cell death at early time 
points during APAP-induced hepatic injury, RIPK3 and MLKL 
deficiency was unable to prevent liver injury in this model (19). 
Other studies further demonstrated that ethanol-induced hepatic 
injury is independent of RIPK1 kinase activity but dependent on 
RIPK3, suggesting that necroptosis does not always require RIPK1 
function (20). A differential damage-dependent requirement of 
RIPK1 and RIPK3 for induction of liver tissue damage was also 
supported by another study (21), indicating that, in addition to 
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detailed understanding of the complex roles of IFN-γ in the devel-
opment of organ-specific autoimmunity is still lacking.
Here, we demonstrate that the pseudokinase MLKL, a key 
factor in the cellular necrosome, is upregulated and activated in 
human AIH and in a model of inflammation-dependent hepatitis. 
Using MLKL-deficient (Mlkl–/–) mice, we have identified MLKL 
as a key trigger of experimental hepatitis in vivo. Surprisingly, we 
found that hepatocellular necrosis in experimental hepatitis is 
driven by a previously unrecognized RIPK3-independent function 
of MLKL. Moreover, we provide compelling evidence that the well-
known cytotoxic activity of the proinflammatory cytokine IFN-γ in 
hepatic inflammation is strongly connected to induction of MLKL 
expression via activation of the transcription factor STAT1.
Results
MLKL is strongly upregulated in hepatocytes of AIH patients and in 
experimental hepatitis. Although necrosis and necroinflammation 
are central features of many liver diseases, the role of programmed 
necrosis in the context of inflammation-dependent hepatocellular 
death remains to be fully determined. Given that MLKL has been 
identified as a key mediator and potential biomarker of regulat-
ed necrosis (7, 16), we initially determined hepatic expression of 
MLKL in patient cohorts with diverse liver diseases of viral, tox-
ic, or autoimmune origin. While the abundance of MLKL tran-
scripts was very low in healthy controls, patients with steatosis, 
and patients with primary biliary cirrhosis, we observed highly 
canonical necroptosis, other related pathways of programmed 
necrosis may contribute to hepatocellular death. In particular, the 
significance of MLKL, the so-far most-terminal known end-stage 
effector of the necroptosis pathway, in the context of liver injury 
remains unclear at present.
Autoimmune hepatitis (AIH) is a severe disease associated 
with chronic inflammation and fibrotic reorganization of liver tis-
sue. The pathology of AIH is characterized by progressive destruc-
tion of the hepatic parenchyma due to incompletely understood 
immune mechanisms that include activation of components of 
both the innate and the adaptive immune system (22). It has been 
shown that the severity of AIH correlated with the hepatic pres-
ence of immune cells that stain positive for the proinflammatory 
cytokines IFN-γ and TNF-α (23). Moreover, several compelling 
findings in mouse models clearly demonstrated that the presence 
and upregulation of these cytokines directly drives hepatocellular 
cytotoxicity (24). Liver-resident or recruited T lymphocytes, NKT 
cells, and NK cells have been identified as primary producers of 
IFN-γ during hepatic inflammation, and IFN-γ signaling provokes 
death of hepatocytes through mechanisms that are poorly under-
stood and likely involve several signaling pathways (25). IFN-γ 
rapidly stimulates STAT1 phosphorylation in vivo and in primary 
hepatocytes (26), and the IFN-γ/STAT1 axis has been suggested 
to block hepatocyte proliferation and induce hepatocyte death via 
apoptosis (27). However, to what extent IFN-γ–induced apoptosis 
contributes to death of hepatocytes in vivo remains unclear, and a 
Figure 1. MLKL is upregulated in areas of severe inflam-
mation and cell death during AIH. (A) Quantification 
of hepatic MLKL mRNA in liver biopsies obtained from 
control (n = 10) or AIH patients (n = 10). **P < 0.01 by paired 
Student’s t test. (B) Representative images of liver tissue 
paraffin sections analyzed for the presence of MLKL by 
immunofluorescence staining. (C) Representative images 
showing double immunofluorescence staining of MLKL 
and albumin in tissue paraffin sections of AIH liver. Inset 
magnification: ×3.38 (D) Representative images of pMLKL-
stained sections of control or AIH liver (arrows demonstrate 
subcellular MLKL localization to plasma membranes;  
images on the right are confocal images) and (E) quantifica-
tion of pMLKL-positive hepatocytes (n = 10 per group).  
***P < 0.001 by paired Student’s t test. Error bars indicate 
± SD, gene expression levels are shown relative to HPRT. 
Scale bar: 5 μm (D, right); 50 μm (C and D, left); 75 μm (B); 
2.77 μm (B, inset).
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in steady-state murine liver tissue was weak, treatment of mice 
with ConA resulted in a rapid and strong increase in both Mlkl 
transcripts and protein, as evidenced by qPCR (Figure 2A and Sup-
plemental Figure 2A), Western blot analysis (Figure 2B and Supple-
mental Figure 2B), and immunohistochemistry (Figure 2C and Sup-
plemental Figure 2F). The absence of specific signals in Mlkl–/– mice 
confirmed the specificity and suitability of the antibody used for 
detection (Supplemental Figure 2C). Immunofluorescent micros-
copy further localized inflammation-dependent MLKL accumula-
tion to hepatocytes, as demonstrated by double staining for MLKL 
and the hepatocyte marker albumin (Figure 2D and Supplemen-
tal Figure 2D). Moreover, expression of Mlkl was pronounced in 
necrotic areas stained positive for the cell death marker TUNEL 
(Figure 2E). Accordingly, we observed that hepatic Mlkl mRNA 
expression correlated well with concentrations of circulating trans-
aminases (Supplemental Figure 2E). Notably, at 3 hours after ConA 
injection, the MLKL protein was equally distributed throughout the 
cytoplasm of hepatocytes (Figure 2F). By contrast and similar to the 
staining pattern we observed in human AIH, at later stages, when 
hepatocytes stained positive for TUNEL, MLKL immunostaining 
was strongly localized to membranous compartments, including 
increased hepatic MLKL expression in patients with AIH (Figure 
1A and Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI87545DS1). Moreover, we 
also observed strong MLKL immunostaining in biopsies obtained 
from AIH patients. Remarkably, MLKL immunostaining in these 
samples was particularly restricted to hepatocytes in areas of 
severe inflammation and hepatocellular death (Figure 1, B and C). 
Phosphorylation of MLKL (pMLKL) and translocation of pMLKL 
to the plasma membrane has been demonstrated to be essential 
for necroptotic cell death (10, 28). Accordingly, strong pMLKL 
signals were present in affected areas in AIH tissue, whereas no 
pMLKL immunostaining was identified in healthy control tis-
sues (Figure 1, D and E). Moreover, confocal microscopy clearly 
revealed subcellular MLKL and pMLKL localization to plasma 
membranes (Figure 1D and Supplemental Figure 1B), suggesting 
that MLKL activation is linked to disease activity in AIH.
In order to study a potential role for MLKL in liver inflam-
mation, we next took advantage of a mouse model in which 
hepatitis is induced by intravenous injection of the lectin con-
canavalin A (ConA), which resembles some aspects of immune- 
mediated hepatitis in humans (29, 30). Whereas MLKL expression 
Figure 2. MLKL is strongly upregulated in hepatocytes in experimentally induced hepatitis. C57BL/6 mice were subjected to ConA or saline treatment 
(mock) as described in the Methods and (A–E) analyzed 7 hours later or (F) at different time points after administration. Experiments were repeated 3 
times with similar results. (A) Quantification of hepatic Mlkl mRNA by qPCR (n > 3 per group). ***P < 0.001 by paired Student’s t test. (B) Detection of 
MLKL protein in tissue lysates by Western blot. Actin was used as loading control. (C) Representative images of liver tissue paraffin sections analyzed 
for the presence of MLKL by immunofluorescence staining. Insets show confocal images. (D and E) Representative images showing double staining for 
(D) MLKL and albumin or (E) MLKL and TUNEL in liver tissue sections (the dashed lines separate necrotic areas from nonnecrotic areas). (F) Represen-
tative MLKL staining in liver tissue of wild-type mice challenged at the indicated time points with ConA. Images on the right are confocal images. Error 
bars indicate +SD, gene expression levels are shown relative to Hprt. Scale bar: 5 μm (F, right); 50 μm (D and F, left); 100 μm (E); 250 μm (C); 1.25 μm (C, 
inset). Magnification in (E): ×3.38.
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during inflammation-dependent cell death. Consistently, IFN-γ 
serum concentrations and production by immune cells, which 
has been shown to be a central trigger for hepatocellular death 
in the ConA model, were not significantly altered in Mlkl–/– mice 
(Figure 3D  and Supplemental Figure 3A). We have previously 
shown that STAT1 activation triggers IFN-γ–dependent hepato-
cellular death (26). In order to investigate whether MLKL defi-
ciency affects hepatic STAT1 signaling, we compared STAT1 
activation in ConA-challenged wild-type and Mlkl–/– mice. While 
hepatic pSTAT1Tyr701 was not detectable in unchallenged animals, 
ConA administration induced a marked induction of pSTAT1Tyr701 
in livers of control and Mlkl–/– mice (Supplemental Figure 3B). In 
addition, primary mouse hepatocytes (PMHs) stimulated ex situ 
with sera of ConA-challenged wild-type or Mlkl–/– mice released 
similar amounts of the cytotoxicity marker LDH (Supplemental 
Figure 3C), suggesting that proinflammatory cytokine responses 
in Mlkl–/– mice are not reduced to an extent that they substantive-
the plasma membrane, the nuclear membrane, and membranous 
compartments with morphological features of mitochondria (Fig-
ure 2F and Supplemental Figure 2, F and G). As it was previously 
shown that phosphorylation of MLKL coincides with MLKL oligo-
merization and membrane translocation, these data strongly impli-
cate MLKL activation in hepatocellular necrosis in the context of 
human and mouse inflammation–dependent liver disease.
Hepatocellular MLKL expression drives ConA-induced hep-
atitis. In order to provide direct functional evidence for a role 
of the MLKL protein in experimental hepatitis, we subjected 
Mlkl–/– mice to ConA treatment. Interestingly, Mlkl–/– animals had 
largely diminished plasma aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) concentrations (Figure 3A), 
compared with those in wild-type controls. Moreover, TUNEL 
staining revealed significantly reduced liver tissue necrosis and 
death of hepatocytes in Mlkl–/– mice (Figure 3, B and C). Our 
data so far clearly point to a hepatocyte-intrinsic role of MLKL 
Figure 3. MLKL expression in hepatocytes drives ConA-induced necrotic cell death. (A–D) C57BL/6 and Mlkl–/– mice were i.v. injected with ConA and 
analyzed 7 hours later. Experiments were repeated 3 times with similar results. (A) Plasma AST/ALT concentrations (n = 4 per group). ***P < 0.001 by 
paired Student’s t test. (B) Representative images of liver sections stained by TUNEL assay. (C) Quantification of necrotic areas in TUNEL assay–stained 
livers of ConA-challenged mice (n = 4 per group). ***P < 0.001 by paired Student’s t test. (D) Quantification of Ifng transcripts in liver lysates of mock- or 
ConA-challenged control and Mlkl–/– mice by qPCR (n > 3 per group). ***P < 0.001 by paired Student’s t test. (E–I) 1 × 107 bone marrow cells isolated from 
control or Mlkl–/– mice were i.v. injected into lethally irradiated C57BL/6 recipient mice. Eight weeks later, mice were injected with ConA (n = 5 per group). (E) 
Plasma AST/ALT concentrations (n = 5 per group). (F) Representative images and quantification (n > 4 per group) of TUNEL assay–stained tissue sections. 
(G) Quantification of serum IFN-γ concentrations and hepatic Ifng transcripts in ConA-treated animals (n = 5 per group). (H) Quantification of hepatic Mlkl 
and Tnfa transcripts (n = 5 per group). (I) Quantification of TNF-α in supernatants of splenocytes isolated from ConA-challenged mice and stimulated 
ex situ with PMA/ionomycin for 24 hours (n = 5 per group). Error bars indicate +SD, gene expression levels are shown relative to Hprt. Scale bar: 250 μm. 
Original magnification in (B and F): ×7.55.
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er, in contrast to that in the ConA model, hepatic Mlkl transcripts 
were not increased and were comparable to saline-treated animals 
(Supplemental Figure 3D), suggesting that MLKL activation is not 
a pivotal cell death trigger in response to APAP. In line with this 
and previous reports (19), Mlkl–/– mice developed strong APAP- 
dependent liver injury, as demonstrated by plasma AST and ALT 
determination (Supplemental Figure 3E), H&E and TUNEL stain-
ing, and quantification of the necrotic areas (Supplemental Figure 
3F). Similarly, no changes in the cell death response were evident 
in PMHs that were isolated from wild-type and Mlkl–/– mice and 
treated ex situ with APAP (Supplemental Figure 3G). Collectively, 
our data demonstrate that MLKL is essential for inflammation- 
induced necrotic hepatocellular death.
RIPK1 but not RIPK3 activity is required for induction of experi-
mental hepatitis. RIPK1 is known to regulate the RIPK3-dependent 
phosphorylation and activation of MLKL, which is a hallmark of 
the canonical necroptosis pathway (7, 31–37). However, the role of 
these RIP kinases in models of experimental induced liver injury 
remains controversial and incompletely understood. Therefore, 
we next aimed to characterize the role of these RIPK proteins for 
the execution of MLKL-dependent hepatocellular death in the 
ly contribute to the protected phenotype of these mice in ConA 
hepatitis. Although it was previously shown that Mlkl–/– mice did 
not display a hematological disturbance under steady-state con-
ditions (31), we further addressed the role of MLKL in hemato-
poietic cells in chimeric mice generated by adoptive transfer of 
wild-type or Mlkl-deficient bone marrow into lethally irradiated 
wild-type recipient mice. Subsequently, administration of ConA 
induced a similar degree of liver injury in both chimeric strains, 
as AST and ALT plasma concentrations and TUNEL positivity 
of hepatocytes were comparable in both groups (Figure 3, E and 
F). Accordingly, in both chimeric strains, hepatic Mlkl, Ifng, and 
Tnfa transcripts; serum concentrations of IFN-γ; and production 
of TNF-α by splenocytes were similarly increased (Figure 3, G–I). 
These data suggest that hepatocyte-intrinsic MLKL expression 
rather than functions in hematopoietic cells are required to medi-
ate ConA-induced liver injury.
Recently, increased pMLKL staining was described around 
central veins in areas with significant damage in patients suffer-
ing from DILI (16). Therefore, we elucidated the potential contri-
bution of MLKL to murine DILI by measurement of hepatic Mlkl 
expression in livers of mice subjected to APAP overdose. Howev-
Figure 4. RIPK1 is upregulated during experimentally induced hepatitis and in human AIH. (A–C) C57BL/6 mice were i.v. injected with ConA and analyzed 
7 hours later. Experiments were repeated 3 times with similar results. (A) Hepatic Ripk1 transcripts were quantified by qPCR (n > 3 per group). **P < 0.01 
by paired Student’s t test. (B) Representative images of liver tissue paraffin sections analyzed for the presence of RIPK1 by immunohistochemistry and 
quantification of RIPK1-positive areas in immunohistochemistry (n > 4 per group). **P < 0.01 by paired Student’s t test. (C) Representative images and 
quantification of double staining of livers sections for RIPK1 and albumin and TUNEL assay. (D and E) Representative images of liver samples of AIH 
patients stained for (D) RIPK1 alone or for (E) RIPK1 and albumin. Error bars indicate +SD, gene expression levels are shown relative to Hprt. Scale bar:  
25 μm (C); 50 μm (E); 75 μm (D); 1.54 μm (D, inset); 500 μm (B).
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ConA model. Similar to MLKL, RIPK1 was profoundly and rap-
idly upregulated at both the mRNA and the protein level in livers 
after ConA treatment (Figure 4, A and B, and Supplemental Figure 
4, A and B). Immunohistochemistry further revealed that RIPK1 
staining clustered around hepatocytes in large foci at areas of pro-
nounced tissue necrosis (Figure 4C and Supplemental Figure 4, 
B and C). In analogy to these findings in mice, we also observed 
a clustered RIPK1 staining pattern in hepatocytes in human AIH, 
whereas RIPK1 was only weakly expressed in the healthy liver 
(Figure 4, D and E). To ascertain whether ConA-induced liver 
injury depends on the kinase activity of RIPK1, we treated wild-
type mice with the RIP1 kinase inhibitor necrostatin-1s (nec-1s) 
prior to ConA injection. Indeed, we observed low serum transam-
inase concentrations (Figure 5A) and reduced necrosis (Figure 5B) 
in mice that received additionally nec-1s. Importantly, inhibition 
of RIPK1 kinase activity by nec-1s blocked the translocation of 
MLKL to the plasma membrane, while the induction of Mlkl gene 
expression in response to ConA was not affected (Figure 5, C and 
D). Notably, pretreatment with nec-1s had no impact on hepatic 
expression of Ifng, suggesting that the kinase activity of RIPK1 is 
involved in ConA-induced hepatocellular death downstream of T 
cell activation (Supplemental Figure 4D). In summary, these data 
indicate that RIPK1 is involved in MLKL-mediated necrotic dam-
age during hepatic inflammation.
Although we observed only weak expression of RIPK3 in 
healthy murine liver tissue as compared with other organs (Supple-
mental Figure 5, A and C), RIPK3 has been reported to be involved 
in the development of liver damage induced by APAP or alcohol 
overdose (17, 20). However, in contrast to Ripk1 and Mlkl, Ripk3 
hepatic transcripts were not increased in response to ConA or in 
human AIH (Supplemental Figure 5B). In line with these findings, 
we were unable to detect RIPK3 in hepatocytes by immunohisto-
chemistry, and even late necrotic hepatocytes, in which the break-
down of plasma membranes is traceable by β-catenin staining, did 
not stain positive for RIPK3 (Figure 6A). By contrast, we observed 
RIPK3 protein positivity in stromal cells that primarily represent 
liver-resident F4/80+ Kupffer cells (Figure 6A and Supplemen-
tal Figure 5E). The absence of specific signals in Ripk3–/– mice 
confirmed the specificity and suitability of the antibody used for 
detection (Supplemental Figure 5, C and D). Consistently, Ripk3 
transcription was low in cultured PMHs (Supplemental Figure 5A). 
To study the functional contribution of RIPK3 to ConA-induced 
hepatocellular death, we next subjected Ripk3–/– mice to ConA 
treatment. In sharp contrast to the protection of mice in the con-
text of RIPK1 inhibition and MLKL deficiency, Ripk3–/– mice had 
high plasma aminotransferase concentrations and developed a 
similar degree of histological liver damage as wild-type control 
mice (Figure 6, B and C, and Supplemental Figure 5, F and G). In 
addition, TUNEL staining and quantification of TUNEL-positive 
cells identified no changes in the degree of hepatocellular necrosis 
in livers of Ripk3–/– mice (Figure 6, B and C). To further evaluate 
these unexpected findings, we analyzed the subcellular localiza-
tion of MLKL in hepatocytes of ConA-injected Ripk3–/– mice by 
confocal microscopy and Western blotting. Interestingly, similar 
to observations in wild-type mice, the MLKL protein clearly accu-
mulated in affected areas of the plasma membrane in Ripk3–/– 
Figure 5. ConA-induced necrotic cell 
death depends on the kinase activity 
of RIPK1. C57BL/6 mice were treat-
ed with vehicle (DMSO) or nec-1s 30 
minutes prior to ConA administration. 
Experiments were repeated 3 times 
with similar results. (A) Plasma  
concentrations of ALT and AST (n = 4  
per group). *P < 0.05, **P < 0.01 by 
paired Student’s t test. (B) Represen-
tative images of H&E- (dashed lines 
represent necrotic areas) and TUNEL 
assay–stained liver tissue sections and 
quantification of necrotic area (n = 4 per 
group). **P < 0.01 by paired Student’s 
t test. (C) Mlkl transcripts in unchal-
lenged mice (mock) and mice treated 
with ConA alone (DMSO) or pretreated 
with nec-1s (nec-1s) were quantified by 
qPCR (n > 3 per group). ***P < 0.001 by 
paired Student’s t test. (D) Representa-
tive images of liver tissue sections from 
ConA-treated mice stained for MLKL in 
combination with TUNEL assay. Images 
on the right are confocal images (MLKL 
staining alone). Error bars indicate +SD, 
gene expression levels are shown rela-
tive to Hprt. Scale bar: 5 μm (D, right); 
50 μm (D, left); 500 μm (B);  
×7.55 (B, insets).
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Figure 6. RIPK3 is dispensable for ConA-induced hepatic injury. C57BL/6 and Ripk3–/– mice were i.v. injected with ConA and analyzed 7 hours later. Exper-
iments were repeated 3 times with similar results. (A) Representative images of liver tissue sections double stained for RIPK3 and β-catenin (confocal 
images are on the right; the dashed line separates necrotic areas from nonnecrotic areas; arrows demonstrate RIPK3-positive immune cells; asterisks mark 
representative hepatocytes). (B) Plasma AST concentrations of ConA-challenged control and Ripk3–/– mice (n > 3 per group) and evaluation of necrotic 
areas in TUNEL assay–stained liver sections of control and Ripk3–/– mice (from C, n > 3 per group). (C) Representative images of immunohistochemical 
(TUNEL assay) staining analysis of hepatic tissue sections. (D) Representative images of MLKL-stained liver tissue sections. (E) Quantification of plasma 
membrane localized MLKL (from D, n > 4 per group). (F) Western Blot analysis demonstrating that endogenous MLKL locates at the plasma membrane 
(PM) in Ripk3–/– mice following ConA treatment. C; cytoplasm. (G) Endogenous MLKL was immunoprecipitated with anti-MLKL antibody in lysates of L929 
cells (treated for 3 hours with TNF-α/zVAD/SMAC mimetic) or in liver lysates of ConA-challenged wild-type or Ripk3–/– mice. (H) Recombinant hRIPK3, 
but not hRIPK1, kinase domain undergoes autophosphorylation and can mediate hMLKL phosphorylation in vitro. Phosphoryl transfer of 32P by 25 ng/μl 
hRIPK1 or hRIPK3 kinase domain in the absence of hMLKL, or 75 ng/μl hMLKL in the absence of kinase, or 2.5 ng/μl hRIPK1 or hRIPK3 in the presence of 
75 ng/μl hMLKL was detected by autoradiography. A Coomassie-stained image of the autoradiograph is shown. The images are representative of triplicate 
experiments. Error bars indicate +SD, gene expression levels are shown relative to HPRT/Hprt. Scale bar: 5 μm (A, right, and D, right); 50 μm (A, left, and D, 
left); 250 μm (C); magnification in (C); ×11.
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Thus, in the setting of inflammation-dependent liver disease, a 
noncanonical type of regulated necrosis that does not require MLKL 
phosphorylation by RIPK3 is a critical trigger of hepatocellular 
death. Notably, RIPK1 itself was not able to directly phosphorylate 
MLKL in in vitro kinase assays, suggesting that additional mecha-
nisms beyond RIPK3-mediated phosphorylation exist, where as-yet 
unidentified kinases could mediate MLKL activation (Figure 6H).
MLKL is not required for LPS/GalN-dependent hepatocellular 
apoptosis. While tissue necrosis has been clearly implicated in 
ConA-induced liver inflammation, the role of hepatocellular apop-
tosis in this model remains controversial. In comparison to mice 
challenged with LPS/D-galactosamine (LPS/GalN) (Figure 7A and 
Supplemental Figure 6A), a model known to be primarily mediat-
ed by apoptotic hepatocellular death, we observed only weak acti-
vation of caspase-3 in liver areas with strong hepatocellular death 
in C57BL/6 wild-type mice subjected to ConA treatment (Figure 
7A and Supplemental Figure 6A). Similarly, no cleaved caspase-3 
signals were present in ConA-treated Mlkl–/– or Ripk3–/– mice and 
mice pretreated with nec-1s (Figure 7A and Supplemental Figure 
6A). These data suggest that apoptotic cell death does not substan-
tially contribute to cell death during ConA-induced liver injury. In 
mice, as demonstrated by immunohistochemical analysis and 
Western blotting (Figure 6, D–F, and Supplemental Figure 5H), 
suggesting that hepatocellular MLKL activation in ConA hepati-
tis does not require RIPK3. Moreover, similar to ConA-challenged 
wild-type animals, hepatocellular necrosis was accompanied by 
profound clustering of RIPK1 into large foci in hepatocytes of 
Ripk3–/– mice (Supplemental Figure 5I). During canonical TNF-α–
mediated necroptosis, MLKL interacts with RIPK3 through its 
kinase-like domain within the necrosome complex (7). In order 
to test whether MLKL interacts with RIP kinases in the context of 
inflammation-dependent programmed hepatocellular necrosis, 
we next immunoprecipitated endogenous MLKL in liver lysates 
of ConA-challenged wild-type and Ripk3–/– animals. Treatment of 
L929 cells with TNF-α plus zVAD and SMAC mimetic served as 
a positive control for transient interaction of MLKL with RIPK3. 
Interestingly, we observed that MLKL is part of a complex that 
contains RIPK1 but not RIPK3 in the setting of ConA hepatitis, 
suggesting that MLKL- and RIPK1-containing protein complexes 
may assemble in the absence of RIPK3 (Figure 6G).
Collectively, these data clearly indicate that RIPK3 but not 
RIPK1 is dispensable for ConA-induced hepatocellular necrosis. 
Figure 7. Caspases are not required for ConA-induced hepatocellular death. (A) Representative images showing double immunofluorescence staining of 
cleaved caspase-3 and TUNEL assay in liver paraffin sections of unchallenged (mock), LPS/-GalN, or ConA-treated mice. (B and C) C57BL/6 or Mlkl–/– mice 
were treated with vehicle (DMSO) or zVAD 15 minutes prior to ConA administration. (B) Plasma AST/ALT concentrations (n > 3 per group). **P < 0.01 by 
paired Student’s t test. (C) Representative images of TUNEL assay–stained liver sections and quantification of necrotic area in liver cross sections of 
ConA-challenged mice (n > 3 per group). ***P < 0.001 by paired Student’s t test. Error bars indicate +SD. Scale bar: 250 μm, magnification ×8.25 (A);  
500 μm, magnification ×8.65 (C).
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IFN-γ–dependent STAT1 activation regulates MLKL expression 
in experimental hepatitis. Having shown that MLKL is strongly 
upregulated in experimental hepatitis and AIH, our next objec-
tive was to identify potential extracellular activators of Mlkl gene 
transcription. We therefore exposed PMHs ex situ to well-known 
triggers for necroptosis or cytokines involved in the pathogenesis 
of inflammatory liver disease. Interestingly, IFN-γ, a key driver of 
liver pathology, profoundly increased Mlkl transcription (Figure 
8A) and protein abundance (Figure 8B). Furthermore, in vivo over-
expression of IFN-γ by hydrodynamic delivery of DNA minicircles 
was sufficient to induce strong hepatic Mlkl gene expression that 
line with this notion, injection of a broad-spectrum caspase inhibi-
tor (zVAD) into control or Mlkl–/– mice before treatment with ConA 
had no effect on tissue necrosis and the levels of serum transami-
nases (Figure 7, B and C, and Supplemental Figure 6B).
In order to study a potential role of MLKL for hepatocellular 
apoptosis, we subjected Mlkl–/– mice to LPS/GalN. However, dif-
ferent from the ConA model, Mlkl–/– mice developed strong LPS/
GalN-dependent liver injury, as demonstrated by plasma AST and 
ALT determination and H&E and cleaved caspase-3 staining (Sup-
plemental Figure 6, C–E), indicating that MLKL deficiency does 
not attenuate hepatocyte apoptosis in this model.
Figure 8. IFN-γ–dependent STAT1 activation regulates MLKL expression in experimental hepatitis. (A) Mlkl transcripts and (B) MLKL protein were 
quantified in PMHs stimulated ex situ with indicated factors (n = 3 per group). (C) IFN-γ expression constructs or empty control vectors (mock) were 
injected into C57BL/6 mice. Four days later, hepatic Mlkl mRNA or MLKL protein (n = 3 per group) was quantified by qPCR or Western blot. The presence 
of MLKL protein in livers was determined by specific immunofluorescent staining. (D) Relative Mlkl mRNA abundance in primary hepatocytes of wild-type 
or Stat1–/– mice stimulated with IFN-γ for 6 hours (n = 3 per group). (E) Quantification of hepatic Mlkl mRNA in vehicle- (mock) or ConA-challenged control 
C57BL/6 mice, Ifng–/– mice, and Stat1–/– mice (n > 3 per group). (F) PMHs were transfected with a Mlkl luciferase promoter construct. Twenty-four hours 
later, cells were stimulated with IFN-γ for 16 hours and firefly luciferase activity was determined (relative to mock group, n = 3 per group). (G) PMHs were 
stimulated with IFN-γ for 45 minutes. Subsequently ChIP was performed using a control antibody (IgG) or anti STAT1pTyr701 mAbs, as detailed in the Meth-
ods. Precipitated DNA fragments were quantified by qPCR using the primer sequences indicated in the sector of Mlkl genomic region in H. Primers covering 
a previously described STAT1-binding site in the mouse Irf1 gene promoter served as a positive control. All experiments were performed at least 2 times 
with similar results. (H) Partial sequence of the mouse genomic Mlkl region upstream of the start codon. Two areas predicted by Matinspector (60) and 
MAPPER (61) as putative STAT1-binding sites were highlighted. TSS, predicted transcriptional start site. Error bars indicate +SD, gene expression levels are 
shown relative to Hprt. Scale bar: 200 μm (C). **P < 0.01, ***P < 0.001 by paired Student’s t test.
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in vivo (Supplemental Figure 7J), and IFN-β stimulation of murine 
BNL liver cells (Supplemental Figure 7K) or MEFs (data not 
shown) resulted in increased Mlkl mRNA abundance, indicating 
that induction of MLKL expression may be a more general feature 
of IFN signaling. As IFN treatment is clinically important in sev-
eral human diseases, this observation may be highly relevant for 
improving such therapeutic strategies. Notably, Ripk1 gene tran-
scription was not regulated by IFN-dependent STAT1 activation 
(Supplemental Figure 8).
Contribution of TNF-α signaling to MLKL-mediated hepatocellu-
lar death. While IFN-γ in vivo overexpression profoundly increased 
ConA-induced liver injury (Supplemental Figure 9, A and B), IFN-γ 
alone was not sufficient to rapidly induce pronounced hepatocel-
lular death (data not shown). Consistent with this, treatment of 
primary hepatocytes with IFN-γ did not affect LDH release in vitro 
(Supplemental Figure 9C), suggesting that, in addition to IFN-γ–
dependent MLKL upregulation, further signals are required for 
induction of inflammation-dependent hepatocellular death. In 
addition to IFN-γ, release of the proinflammatory cytokine TNF-α 
has been identified as an important contributor to liver injury 
(39). Given the well-known role of TNF-α in regulated necrosis, 
we therefore next addressed the role of this factor in the context 
of hepatic MLKL and RIPK1 activation. Although Tnfa transcripts 
were strongly induced in the course of ConA challenge and Tnfr1–/– 
mice displayed protection, confirming previously published data 
(40) (Supplemental Figure 10, A and B, and data not shown), 
hepatic Mlkl and Ripk1 expression was comparable between ConA- 
challenged control and Tnfr1–/– mice (Supplemental Figure 8E and 
Supplemental Figure 10, C and D), indicating that TNF-α signal-
ing is not required for induction of Mlkl or Ripk1 gene transcrip-
tion. By contrast, RIPK1 foci formation and MLKL translocation to 
membranous cellular compartments were profoundly reduced in 
ConA-treated Tnfr1–/– mice as compared with controls (Supplemen-
tal Figure 10, E and F). In summary, these data implicate TNF-α in 
MLKL activation during experimentally induced hepatitis. Thus, 
IFN-γ and TNF-α synergistically drive inflammation-dependent 
hepatocellular death by regulation of MLKL transcription and its 
subsequent activation (Supplemental Figure 11).
Discussion
Irrespective of the cause of liver injury, hepatocellular death is a 
pathophysiologically important feature of many acute and chronic 
liver diseases (15). In some liver disorders with a strong inflamma-
tory component, such as AIH, destruction of the liver parenchyma 
by cellular or soluble immune factors is a central trigger of dis-
ease manifestation and progression. However, multiple signaling 
pathways are activated during hepatic inflammation, and so far 
precise therapeutically relevant mechanistic knowledge of the cell 
death machinery in hepatic diseases is limited. Here, we provide 
compelling evidence that the pseudokinase MLKL is an essential 
mediator of inflammation-driven hepatocellular necrosis in mice. 
By contrast, the activity of RIPK3 was not required for MLKL- 
directed death of hepatocytes in this setting, indicating the presence 
of a previously undescribed form of MLKL activation that may be 
physiologically relevant in liver diseases. On a molecular level, we 
further unraveled that the highly increased Mlkl gene expression in 
hepatocytes during inflammation was linked to STAT1 activation 
was restricted to hepatocytes, as demonstrated by MLKL-specific 
immunostaining (Figure 8C). Given that IFN-γ has been shown 
to primarily mediate its biological function via the transcription 
factor STAT1, we stimulated primary hepatocytes of control and 
Stat1–/– mice with IFN-γ and measured Mlkl expression. In support 
of an IFN-γ/STAT1–dependent regulation of Mlkl gene expres-
sion, IFN-γ did not induce Mlkl transcription in Stat1–/– mice or 
STAT1-deficient hepatocytes (Figure 8D and Supplemental Fig-
ure 7A). IFN-γ/STAT1 signaling is essential for ConA-mediated 
liver injury, and T cells and NKT cells were identified as primary 
producers of IFN-γ in this model (26, 29). Thus, we next analyzed 
the expression of Mlkl in ConA-treated Stat1–/–, Ifng–/–, and lymph-
openic Rag1–/– mice. Remarkably, in all three strains hepatic Mlkl 
expression was not induced in vivo, and this correlated to reduced 
hepatocyte death and tissue damage (Figure 8E and Supplemen-
tal Figure 7, B–E). Collectively, these data demonstrate that in vivo 
Mlkl expression is induced by an IFN-γ/STAT1–dependent path-
way requiring the presence of lymphocytes.
Interestingly, in silico analysis identified several poten-
tial STAT1-binding sites in the genomic region upstream of the 
Mlkl-coding sequence (Figure 8H), indicating that Mlkl gene tran-
scription may be directly induced by IFN-γ–dependent STAT1 
activation. To address this question, we cloned upstream DNA 
fragments of the Mlkl genomic region and generated luciferase 
reporter constructs for reporter gene assays. Interestingly, basal 
luciferase activity after transient transfection of an approximate-
ly 1-kb fragment, including the putative Mlkl transcriptional start 
site, into primary hepatocytes strongly increased upon IFN-γ 
stimulation (Figure 8F). Similar results were obtained in IFN-γ–
treated human embryonic kidney cells, BNL cells, and mouse 
embryonic fibroblasts (MEFs) (Supplemental Figure 7F and data 
not shown). Moreover, ChIP assays and quantitative ChIP using a 
pSTAT1-specific antibody for precipitation identified STAT1 bind-
ing to predicted γ-activated sequences in the Mlkl promoter region 
in IFN-γ–stimulated BNL liver cells (Figure 8G). Binding of STAT1 
to a previously described site in the Irf1 promoter served as a pos-
itive control (38) (Figure 8G). In summary, these data suggest that 
the proinflammatory cytokine IFN-γ directly regulates Mlkl gene 
transcription via activation of STAT1.
Notably, while previous studies implicated the IFN-γ/STAT1 
pathway in provoking hepatocellular death by induction of apop-
tosis (25), our data support the notion that this pathway promotes 
MLKL-mediated programmed necrosis rather than apoptosis.
Having shown that IFN-γ, the sole member of the type II IFNs, 
induced Mlkl gene transcription in hepatocytes, we next analyzed 
the capacity of type I and type III IFNs to regulate MLKL. Thus, 
we next tested the contribution of type I and type III IFNs to reg-
ulation of MLKL during ConA-induced liver injury. In contrast 
to Ifng–/– mice, Ifnar–/– and Il28r–/– (also known as Ifnlr1–/–) mice 
showed a comparable increase in hepatic Mlkl mRNA compared 
with wild-type controls, suggesting that, indeed, IFN-γ is the key 
driver for Mlkl gene expression during these experimental condi-
tions (Supplemental Figure 7G). However, in primary hepatocytes 
the type I IFN IFN-β strongly increased hepatic Mlkl transcripts in 
a STAT1-dependent manner in vitro, whereas type III IFN (IFN-λ) 
stimulation did not upregulate Mlkl (Supplemental Figure 7, H 
and I). Likewise, IFN-β treatment increased hepatic Mlkl mRNA 
Downloaded from http://www.jci.org on November  3, 2016.   https://doi.org/10.1172/JCI87545
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 3 5 6 jci.org   Volume 126   Number 11   November 2016
oligomerization, membrane translocation, and permeabilization. 
Moreover, additional phosphorylation sites in the MLKL protein 
might control its activation and subsequent programmed necrosis 
independent of RIPK3 (28). As a result, the responsible kinases and 
mechanisms underlying MLKL regulation by phosphorylation at 
these additional sites remain matters of ongoing interest.
In summary, these results provide a rationale for investigation 
of MLKL as a possible diagnostic biomarker for hepatocellular 
necrosis in AIH and other inflammation-dependent liver diseases. 
In addition, our findings support the concept that specific mod-
ulation of the MLKL pathway may be therapeutically relevant to 
decrease inflammation-dependent hepatocellular death and its 
fatal consequences in chronic human liver disorders.
While we provided compelling evidence for an essential role 
of MLKL during lymphocyte-mediated hepatitis, MLKL deficien-
cy did not ameliorate APAP-induced liver injury in mice. Although 
previous studies have shown that RIPK3 contributes to necrotic 
cell death after APAP overdose (17, 21), oxidative stress–related 
mitochondrial damage may be closely related to death of hepato-
cytes in this model (47). This indicates that in hepatocytes sev-
eral parallel mechanisms exist to execute necrotic cell death in 
vivo as previously shown in vitro for a variety of other cell types 
(15). Whereas APAP overdose and other forms of DILI are char-
acterized by sterile inflammation, hepatocellular death in the 
ConA model and potentially AIH depends to a large extent on the 
release of cytokines by T lymphocytes, NKT cells, and NK cells. 
Accordingly, we identified IFN-γ, a cytokine previously described 
as essential for ConA-induced hepatitis, as a critical mediator of 
MLKL-dependent hepatocellular death. For the first time to our 
knowledge, we describe that IFN-γ signal transduction in hepato-
cytes, via activation of STAT1 and transactivation of the Mlkl pro-
moter, rapidly increased the amount of MLKL transcripts and pro-
tein, which are low under steady-state conditions.
PMHs display spontaneous cell death during long-term cell 
culture but show rather low sensitivity to necroptosis induction 
by TNF-α/zVAD/SMAC mimetic treatment (43, 48). Howev-
er, pretreatment of mice or cells with IFN-γ upregulated Mlkl in 
hepatocytes and increased their susceptibility toward cell death 
(Supplemental Figure 12). Similarly, it was recently reported that 
MEFs may require IFN pretreatment for effective necroptosis 
induction (49), indicating that sensitization of cells with IFNs may 
represent a general mechanism supporting programmed necrosis. 
IFN-induced necroptosis was described in macrophages in the 
presence of caspase inhibitors. Interestingly, in this study Ifnar1–/– 
macrophages were resistant to TNF-α/zVAD–induced necropto-
sis, indicating that feedback signaling through IFNs is essential 
for sustained activation of RIP kinases in response to TNF-α, LPS, 
or poly(I:C) (50). Our data now provide compelling evidence that, 
in addition to such other cell death–promoting properties of IFNs, 
the transcriptional regulation of MLKL by these factors is par-
ticularly important in cells that do not express substantial basal 
levels of MLKL, such as hepatocytes. Thus, while previous stud-
ies implicated the IFN-γ/STAT1 pathway in promoting hepato-
cellular death by induction of apoptosis (25), our data support the 
notion that this pathway provokes MLKL-mediated programmed 
necrosis of hepatocytes rather than apoptosis. These data add 
to the molecular understanding of IFN-mediated tissue damage 
by the proinflammatory and cytotoxic cytokine IFN-γ, suggesting 
that IFN signaling–dependent regulation of MLKL is an important 
mechanism of sensitization of cells to regulated necrosis.
We demonstrate that elevated levels of MLKL mRNA and pro-
tein in hepatocytes relate to hepatic injury both during experimen-
tally induced hepatitis and AIH in humans. Importantly, its upreg-
ulation in hepatitis clearly correlated to strong MLKL translocation 
to the plasma membrane and other membranous compartments, 
indicating that MLKL-dependent disruption of cellular integrity 
contributes to inflammation-dependent death of hepatocytes. In 
current models of necroptosis, MLKL plasma membrane transloca-
tion is driven by RIPK3-dependent phosphorylation (10, 11, 16, 41, 
42). Importantly, while we observed a strong attenuation of acute 
liver damage in Mlkl–/– mice, our data provided several lines of evi-
dence that, during experimental hepatitis, MLKL activation and 
translocation to membranous compartments occurs independent-
ly of RIPK3. Consistently, Ripk3–/– mice developed ConA-induced 
hepatitis as severe as control mice. Accordingly, we observed 
only low basal levels of RIPK3 in hepatocytes, and similar to other 
reports (19, 43), RIPK3 positivity was rather limited to nonparen-
chymal cells, particularly Kupffer cells. Although we have previ-
ously shown that RIPK3 is upregulated in intestinal epithelial cells 
undergoing TNF-α–triggered necroptosis (8), we were unable to 
detect induction of RIPK3 mRNA or protein in hepatocytes during 
the course of experimentally induced hepatitis or in human AIH. In 
line with this, a recent study demonstrated that RIPK3 expression 
in hepatocytes is dispensable for inflammatory liver injury (43).
While our data unexpectedly identified a RIPK3-indepen-
dent function of MLKL, RIPK1 was not dispensable for ConA- 
induced hepatocellular death. A pharmacological approach to 
block RIPK1 kinase function was sufficient to markedly attenuate 
ConA-induced liver injury and to block translocation of MLKL to 
the plasma membrane. In line with previous reports (43), inhibition 
of RIPK1 kinase activity did not markedly influence immune cell–
mediated cytokine production. These results clearly implicate that 
hepatocyte-intrinsic RIPK1 kinase activity is required for MLKL 
plasma membrane translocation. In summary, these data implicate 
that RIPK1 and RIPK3 display divergent roles during hepatocellu-
lar injury and that both RIP kinases may be, independently of each 
other, members of cell death–related functional platforms. Further 
studies will have to provide more detailed information about the 
composition of MLKL-containing complexes, as the current notion 
that MLKL is solely activated by RIPK3-mediated phosphorylation 
is evidently not ubiquitous to all cellular contexts. This is supported 
by studies investigating the evolutionary origin of necroptosis that 
uncovered that RIPK3 is absent in many organisms, such as birds 
and in mammals of the superorder Xenarthra and in the Mono-
tremata, whereas MLKL is present and RIPK1 retains its RHIM 
domain (44, 45). Interestingly, one of the phosphorylation sites in 
MLKL identified thus far and the intrinsic membrane-permeabi-
lization function of MLKL seem to be conserved, even in species 
that have lost RIPK3, indicating that other kinases, such as RIPK1, 
are likely to be additional modulators of MLKL activation (44, 46). 
However, in our study we did not observe that RIPK1 directly phos-
phorylates MLKL during ConA hepatitis, indicating that, under 
these experimental conditions, an as-yet-unidentified kinase is 
likely to activate MLKL by phosphorylation and promote MLKL 
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In some experiments, PMHs, BNL cells, or MEFs were stimulated 
with 100 ng/ml of recombinant mouse IFN-β (R&D Systems), 100 ng/
ml recombinant mouse IFN-γ (Preprotech), 100 ng/ml recombinant 
mouse IL-28 (IFN-λ, R&D Systems), 8 mM APAP, or murine sera in 
a final concentration of 3%. HEK293T cell were stimulated with 100 
ng/ml recombinant human IFN-γ (Roche). For cytokine release, iso-
lated splenocytes were cultured in RPMI 1640 supplemented with 
PMA (50 ng/ml, Calbiochem) in combination with ionomycin (500 
ng/ml, Cayman) for 24 hours. Cell viability was measured using the 
Cytotoxitiy Detection Kit (LDH, Roche) or the Cell Death Detection 
ELISAPLUS Kit (Roche) accordingly to the manufacturer’s instruction. 
Cell viability was calculated as follows: cell viability level = 1/mean cell 
viability of the control group.
Cytokine measurements. For determination of mouse IFN-γ or 
TNF-α, specific DuoSet ELISA Kits from R&D Systems were used. 
ELISA was performed according to manufacturer’s instructions.
Transient transfections and luciferase assays. An approximately 1-kb 
fragment, including the putative mouse Mlkl gene promoter sequence, 
was identified using the Genomatix software suite (http://www.
genomatix.de) and amplified using the PfuUltra II Fusion HS DNA 
Polymerase (Aligent Technologies) out of tail genomic DNA using 
the primers 5′-ccctacttgggtaacttcac-3′ and 5′-gaatgccattcctcgatctc-3′. 
The PCR product was finally cloned upstream of the firefly luciferase 
open reading frame in the pGL-4.1 vector (Promega) using the NheI 
and HindIII sites. For the transfection of HEK293T or PMH cells, the 
cells were seeded at 300,000 (HEK293T) or 500,000 (PMH) cells 
per 6-well plate and transfected 1 day after with 5 μg DNA using Lipo-
fectamine 2000 transfection reagent according to the manufacturer’s 
instructions. The Luciferase Reporter Assay System from Promega 
was used for the analysis of luciferase activity in cell lysates according 
to the manufacturer’s instructions.
ChIP assay. Chip assay was performed using the SimpleChIP Enzy-
matic Chromatin IP Kit (Magnetic Beads) from Cell Signaling accord-
ingly to the manufacturer’s instruction. In brief, BNL cells were stimu-
lated with IFN-γ for 45 minutes, fixed by addition of 1% formaldehyde, 
lysed, and treated with 1,200 U Micrococcus nuclease. Protein-DNA 
complexes were immunoprecipitated overnight using anti-pSTAT1Tyr701 
(Cell Signaling, catalog 9167) or control antibodies (Cell Signaling, cat-
alog 2729) and protein A–coupled magnetic beads. Real-time PCR on 
silica column–purified DNA was performed using the following prim-
ers: STAT1-Mlkl 5′-gaactgagcgatagac-3′ and 5′-cgaaaccaaccctaag-3′ or 
STAT1-Irf1 5′-agcacagctgacttcc-3′ and 5′-cttagactgtacgtcc-3′ Quantifi-
cation of DNA by qPCR was performed as follows: percentage input = 
2% × 2 (C[T] 2% input sample – C[T] IP sample), where C[T] denotes 
the threshold cycle of the PCR reaction.
IP and immunoblotting. Proteins were isolated from liver biopsies 
using Cell lysis buffer (Cell Signaling) supplemented with 1 mM PMSF 
(Cell Signaling). Isolation of plasma membrane proteins was performed 
using the Plasma Membrane Protein Extraction Kit (catalog ab65400, 
abcam) accordingly to the manufacturer’s instructions. Lysates were 
then centrifuged at 18,000 g for 20 minutes. For IP experiments super-
natants were precleared and subsequently immunoprecipitated with 
anti-MLKL antibody (1:50, Merck Millipore, clone 3H1) at 4°C over-
night. Subsequently, lysates were further incubated with protein G–
coupled magnetic beads for 20 minutes at room temperature. After IP, 
the beads were washed 4 times with lysis buffer, and the immunopre-
cipitated proteins were subsequently eluted with SDS sample buffer. 
and establish a link between proinflammatory cytokine produc-
tion during inflammation and regulated necrosis beyond TNF-α–
induced signal transduction. Of note, IFNs are not only implicated 
in many autoimmune diseases but broadly used in the therapy of, 
for example, viral hepatitis and multiple sclerosis. Therapy is com-
monly associated with adverse side effects, such as hepatoxicity, 
autoantibody production, and AIH, and this leads to dose reduc-
tions or termination of therapy (51, 52). IFN-mediated induction 
of MLKL and subsequent activation of hepatocellular necrosis 
may significantly contribute to these side effects, and this obser-
vation may thus be relevant for the future of IFN-related therapies. 
Such strategies may involve cotreatment of patients with IFNs and 
chemical compounds that inhibit the activity of MLKL.
Collectively, our data uncover a form of programmed necrot-
ic cell death that is dependent on the RIPK1/MLKL axis but does 
not require RIPK3. Depending on the physiological context, MLKL 
has the capacity to promote RIPK3-mediated necroptosis or alter-
natively triggers IFN-mediated RIPK3-independent programmed 
necrosis. In addition, our results suggest a physiological relevance 
for IFN-triggered MLKL-dependent death in the pathogenesis of 
inflammation-dependent liver injury such as AIH.
Methods
Animals and housing of mice. C57BL/6, Rag1–/–, Stat1–/–, and Tnfr1–/– 
mice were obtained from The Jackson Laboratory. Ripk3−/− mice were 
described previously (53). Ifng–/– and Ifnar–/– mice were provided by 
U. Schleicher. Mlkl–/– mice were provided by J. Murphy. Throughout, 
we used either C57BL/6J or littermate controls to exclude strain- 
dependent differences in disease susceptibility. Mice were routinely 
screened for pathogens according to FELASA guidelines.
Animal model of liver injury. LPS and GalN (catalog G1639) were 
obtained from Sigma-Aldrich. ConA was from Merck Millipore (cata-
log 234567). APAP was from Braun. Z-Val-Ala-DL-Asp-fluoromethyl-
ketone (zVAD) was from Bachem (catalog N-1510). Nec-1s was from 
BioVision (catalog 2263). ConA was administered intravenously (25 
mg/kg body weight) alone or in combination with nec-1s (400 μg, i.p., 
30 minutes) or zVAD (250 μg/mouse, i.p., 15 minutes) before ConA 
administration. Stock solutions of nec-1s were prepared in DMSO 
(final concentration 0.5%). D-GalN (1 mg/kg) was injected i.p. 1 hour 
prior to administration of LPS (100 μg/kg, i.p.). APAP (400 mg/kg) 
was injected i.p. after overnight fasting. Plasma concentrations of AST 
and ALT were measured in the clinical chemistry unit of the University 
Medical Center Erlangen.
For generation of bone marrow chimeras, 1 × 107 cells from femurs 
and tibias of donor mice were intravenously injected into lethally irra-
diated (10 Gy) recipient C57BL/6 mice. Mice were left to recover for 
8 weeks before ConA was administrated.
Cell lines. HEK293T and BNL cells were obtained from ATCC. 
HEK293T cells, BNL cells, and MEFs were cultured in Dulbecco’s Mod-
ified Eagle Medium or RPMI 1640 containing penicillin (100 U/ml, 
GIBCO), streptomycin (100 μg/ml, GIBCO), 10% FCS, L-glutamine 
(200 mM), sodium pyruvate (400 mM), and glucose (4.5 g/l). Primary 
hepatocytes were isolated as described previously (54). Purified hepato-
cytes were seeded in collagen-coated culture plates and cultured using 
the following medium: William’s Medium E containing 100 U/ml peni-
cillin, 100 μg/ml streptomycin, 120 mg/ml gentamicin, 4% FCS, 2 mM 
glutamine, 100 nM insulin, and 100 nM dexamethasone.
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dex-200 gel filtration columns (GE Healthcare) in 200 mM NaCl, 20 
mM HEPES, pH 7.5, 5% glycerol; concentrated by centrifugal ultrafil-
tration to 6.5–7 mg/ml; aliquoted; and snap frozen in liquid N2, before 
storage at –80°C until required.
In vitro kinase assays on purified proteins. Kinase assays for purified 
recombinant kinase domains of hRIPK1 and hRIPK3 in the presence 
or absence of recombinant human MLKL were performed essential-
ly as described previously (31, 58). Briefly, 3 μg recombinant hMLKL 
was incubated in the absence or presence of 100 ng of recombinant 
hRIPK1 or hRIPK3 for 5 minutes at 25°C after the reaction was initi-
ated by addition of 5 μCi 32P-γ-ATP and 37.5 μM cold ATP in a 40-μl 
reaction. In parallel, 1 μg of either hRIPK1 or hRIPK3 kinase domain 
was reacted analogously in the absence of substrate. Kinase reaction 
buffer comprised 100 mM NaCl, 20 mM Tris, pH 8, 4 mM MgCl2, 0.1 
mM DTT, and 1 mg/ml BSA. Reactions were terminated by boiling 
in 1× reducing SDS-PAGE loading buffer for 5 to 10 minutes before 
one-quarter of each reaction was resolved by 4%–12% Bis-Tris reduc-
ing SDS-PAGE. The gel stained with SimplyBlue SafeStain (Thermo 
Fisher) was dried under a vacuum and exposed to a phosphor screen 
for 16 hours before scanning using a Typhoon imager (GE Healthcare).
Statistics. Statistical analysis was performed using the 2-tailed 
Student’s t test. P values of less than 0.05 were considered significant.
Study approval. Animal protocols were approved by the Institu-
tional Animal Care and Use Committee of the Regierung von Unter-
franken. All studies with human material were approved by the ethics 
committee of the University Hospital of Erlangen. The diagnosis of 
AIH was defined according to the guidelines of the European Associ-
ation for the Study of Liver Disease (59) and was based on compatible 
symptoms and signs of AIH, elevated ALT and AST, increased serum 
IgG, serological findings (elevated antinuclear antibodies, smooth 
muscle antibody, soluble liver antigen, or liver kidney/microsome 
antibodies), and histological findings, such as interface hepatitis and 
plasma cell infiltration. The acute forms of DILI can be divided into 
hepatocellular, cholestatic, and mixed forms. In this study cohort of 
DILI patients, all cases presented mixed forms indicated by the pres-
ence of hepatocellular and cholangiocellular damage. The extent of 
hepatocellular and cholangiocellular toxicity was variable but never 
purely hepatocellular or cholestatic. Other conditions that may cause 
hepatitis, including viral, drug-induced, cholestatic, metabolic, and 
hereditary disorders, have been excluded in these patients.
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